J Clin Oncol: A randomized trial by Professor Ming Shi's team from Sun Yat-sen University Cancer Hospital confirmed that the use of FOLFOX for hepatic arterial infusion chemotherapy can significantly prolong the survival of patients with unresectable large liver cancer!

In a previous phase II clinical trial, the use of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for hepatic artery infusion chemotherapy (HAIC) resulted in greater than transarterial chemoembolization (TACE) in unresectable large hepatocellular carcinoma.
Higher treatment response
.

Shi Ming, director of the Department of Liver Oncology, Sun Yat-sen University Tumor Hospital, led a team to carry out a randomized, multi-center, open-label clinical trial to compare unresectable large liver cancer (tumor diameter ≥ 7cm) The overall survival of the patient
.

Patients with unresectable large liver cancer were randomly assigned to the FOLFOX-HAIC group 1:1 (on day 1 infusion of oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2, followed by infusion of fluorouracil 2400 mg /m2, lasting 24 hours, every 3 weeks treatment course) or TACE group (50 mg epirubicin, 50 mg lobaplatin, lipiodol and polyvinyl alcohol particles)
.

Overall survival and progression-free survival of the two groups

From October 1, 2016 to November 23, 2018, a total of 315 patients were randomly assigned to the FOLFOX-HAIC group (n=159) or TACE group (n=156)
.

The occurrence of adverse events in the two groups

In addition, the incidence of serious adverse events in the TACE group was higher than that in the FOLFOX-HAIC group (30% vs 19%; P=0.
03)
.

Qi-Jiong Li, et al.